The Place of Biosimilars in the Therapeutic Strategy in Patients
with Moderate-to-Severe Plaque Psoriasis

Aleksandra Lesiak; Joanna Narbutt; Agnieszka B. Owczarczyk-Saczonek; Witold Owczarek; Maciej Pastuszczak; Adam Reich; Jacek Szepietowski; Irena Walecka; Julia M. Feldman

doi:10.5114/dr.2025.153426

Streszczenie

2/2025 vol. 112

Artykuł przeglądowy

The Place of Biosimilars in the Therapeutic Strategy in Patients with Moderate-to-Severe Plaque Psoriasis

Aleksandra Lesiak ¹

,

Joanna Narbutt ¹

,

Agnieszka B. Owczarczyk-Saczonek ²

,

Witold Owczarek ³

,

Maciej Pastuszczak ⁴

,

Adam Reich ⁵

,

Jacek C. Szepietowski ⁶

,

Irena Walecka ⁷

,

Julia M. Feldman ⁸

Department of Dermatology, Pediatric Dermatology and Oncology, Laboratory of Autoinflammatory, Genetic and Rare Skin Disorders, Medical University of Lodz, Poland
Department of Dermatology, Sexually Transmitted Diseases and Clinical Immunology, University of Warmia and Mazury, Olsztyn, Poland
Department of Dermatology, Military Institute of Medicine, National Research Institute, Warsaw, Poland
Department of Dermatology in Zabrze, Silesian Medical University in Katowice, Poland
Department of Dermatology, Institute of Medical Sciences, College of Medical Sciences, University of Rzeszow, Rzeszow, Poland
Division of Dermatology, Venereology and Clinical Immunology, Faculty of Medicine, Wroclaw University of Science and Technology, Wroclaw, Poland
Department of Dermatology, CMKP/PIM MSWiA, Warsaw, Poland
Sandoz Polska

Dermatol Rev/Przegl Dermatol 2025, 112, 93-103

DOI: https://doi.org/10.5114/dr.2025.153426

Data publikacji online: 2025/06/30

Pełna treść artykułu

AMA

Lesiak A, Narbutt J, Owczarczyk-Saczonek A, et al. The Place of Biosimilars in the Therapeutic Strategy in Patients with Moderate-to-Severe Plaque Psoriasis. Dermatology Review/Przegląd Dermatologiczny. 2025;112(2):93-103. doi:10.5114/dr.2025.153426.

APA

Lesiak, A., Narbutt, J., Owczarczyk-Saczonek, A., Owczarek, W., Pastuszczak, M., & Reich, A. et al. (2025). The Place of Biosimilars in the Therapeutic Strategy in Patients with Moderate-to-Severe Plaque Psoriasis. Dermatology Review/Przegląd Dermatologiczny, 112(2), 93-103. https://doi.org/10.5114/dr.2025.153426

Chicago

Lesiak, Aleksandra, Joanna Narbutt, Agnieszka B. Owczarczyk-Saczonek, Witold Owczarek, Maciej Pastuszczak, Adam Reich, and Jacek C Szepietowski et al. 2025. "The Place of Biosimilars in the Therapeutic Strategy in Patients with Moderate-to-Severe Plaque Psoriasis". Dermatology Review/Przegląd Dermatologiczny 112 (2): 93-103. doi:10.5114/dr.2025.153426.

Harvard

Lesiak, A., Narbutt, J., Owczarczyk-Saczonek, A., Owczarek, W., Pastuszczak, M., Reich, A., Szepietowski, J., Walecka, I., and Feldman, J. (2025). The Place of Biosimilars in the Therapeutic Strategy in Patients with Moderate-to-Severe Plaque Psoriasis. Dermatology Review/Przegląd Dermatologiczny, 112(2), pp.93-103. https://doi.org/10.5114/dr.2025.153426

MLA

Lesiak, Aleksandra et al. "The Place of Biosimilars in the Therapeutic Strategy in Patients with Moderate-to-Severe Plaque Psoriasis." Dermatology Review/Przegląd Dermatologiczny, vol. 112, no. 2, 2025, pp. 93-103. doi:10.5114/dr.2025.153426.

Vancouver

Lesiak A, Narbutt J, Owczarczyk-Saczonek A, Owczarek W, Pastuszczak M, Reich A et al. The Place of Biosimilars in the Therapeutic Strategy in Patients with Moderate-to-Severe Plaque Psoriasis. Dermatology Review/Przegląd Dermatologiczny. 2025;112(2):93-103. doi:10.5114/dr.2025.153426.

Streszczenie

The Place of Biosimilars in the Therapeutic Strategy in Patients with Moderate-to-Severe Plaque Psoriasis

Udostępnij

Dostępne w

Zintergrowane z

Zasady redakcyjne